by Jordana Choucair | Nov 23, 2022 | Public Health/Prevention
The Biden administration launched a six-week push to increase Americans’ COVID-19 booster vaccinations heading into the holiday season. The campaign will focus on reaching seniors and the communities that were hardest hit by COVID-19 by expanding access, increasing...
by Jordana Choucair | Nov 22, 2022 | Inequities and SDOH
A recent Centers for Disease Control and Prevention (CDC) analysis indicates that people with impaired vision aren’t getting the health care they need. According to the study, 50.2 percent of people with vision impairment said they had fair or poor general health...
by Jordana Choucair | Nov 22, 2022 | Opioid/Substance Use Disorders
A Kaiser Health News (KHN) article examines how states are planning to spend the $26 billion for the opioid settlement fund. The settlement includes specific parameters for how the states can spend the money: 70 percent must be used for opioid-related expenses (e.g.,...
by Jordana Choucair | Nov 22, 2022 | Providers
According to recent reports, health systems nationwide have seen a significant rise in denied claims over the past year. A Kaufman Hall report found that approximately 67 percent of health care leaders reported an increase in claim denials over the past year, compared...
by Jordana Choucair | Nov 21, 2022 | M&A
The Department of Justice (DOJ) and two states – New York and Minnesota – issued a notice to appeal a judge’s decision to dismiss their antitrust challenge of UnitedHealth’s acquisition of Change Healthcare. The DOJ sued to block the deal in February,...
by Jordana Choucair | Nov 21, 2022 | M&A
Merck & Co. agreed to acquire cancer developer Imago BioSciences Inc. in a deal valued at $1.35 billion. The deal will add new revenue streams as Merck’s patent deal for cancer treatment Keytruda is set to expire early next year and grow its presence in the...
Recent Comments